Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 2, 2011, Pages 123-129

  Graefe Mody, Ulrike ^a   Rose, Peter ^a   Ring, Arne ^a   Zander, Kerstin ^a   Iovino, Mario ^a   Woerle, Hans Juergen ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Drug interaction; Glibenclamide; Glyburide; Linagliptin; Pharmacokinetics; Type 2 diabetes

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLIBENCLAMIDE; LINAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79955712959     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-091     Document Type: Article

References (27)

1. Kahn, S. E., Zraika, S., Utzschneider, K. M. and Hull, R. L.: The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia, 52: 1003-1012 (2009).
2. Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R. and Zinman, B.: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32: 193-203 (2009).
3. Thomas, L., Eckhardt, M., Langkopf, E., Tadayyon, M., Himmelsbach, F. and Mark, M.: (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro- purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase 4 inhibitors. J. Pharmacol. Exp. Ther., 325: 175-182 (2008).
4. Hüttner, S., Graefe-Mody, E. U., Withopf, B., Ring, A. and Dugi, K. A.: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J. Clin. Pharmacol., 48: 1171-1178 (2008).
5. Fuchs, H., Tillement, J.-P., Urien, S., Greischel, A. and Roth, W.: Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J. Pharm. Pharmacol., 61: 55-62 (2009).
6. Retlich, S., Duval, V., Ring, A., Staab, A., Hüttner, S., Jungnik, A., Jaehde, U., Dugi, K. A. and Graefe-Mody, U.: Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin. Pharmacokinet., 49: 829-840 (2010).
7. Retlich, S., Duval, V., Graefe-Mody, U., Jaehde, U. and Staab, A.: Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J. Clin. Pharmacol., 50: 873-885 (2010).
8. Retlich, S., Withopf, B., Greischel, A., Staab, A., Jaehde, U. and Fuchs, H.: Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats. Biopharm. Drug Dispos., 30: 422-436 (2009).
9. Heise, T., Graefe-Mody, E. U., Hüttner, S., Ring, A., Trommeshauser, D. and Dugi, K. A.: Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes. Metab., 11: 786-794 (2009).
10. Blech, S., Ludwig-Schwellinger, E., Graefe-Mody, E. U., Withopf, B. and Wagner, K.: The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab. Dispos., 38: 667-678 (2010).
11. Graefe-Mody, U., Huettner, S., Stähle, H., Ring, A. and Dugi, K. A.: Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int. J. Clin. Pharmacol. Ther., 48: 367-374 (2010).
12. Ashcroft, F. M.: Mechanisms of the glycaemic effects of sulfonylureas. Horm. Metab. Res., 28: 456-463 (1996).
13. Vila-Carriles, W. H., Zhao, G. and Bryan, J.: Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J., 21: 18-25 (2007).
14. ® (Glyburide USP tablets) Prescribing information, July 2009. Available at: http://products.sanofi-aventis.us/diabeta/diabeta.pdf (accessed 27 Aug 2010).
15. Zharikova, O. L., Fokina, V. M., Nanovskaya, T. N., Hill, R. A., Mattison, D. R., Hankins, G. D. and Ahmed, M. S.: Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem. Pharmacol., 78: 1483-1490 (2009).
16. Zhou, L., Naraharisetti, S. B., Liu, L., Wang, H., Lin, Y. S., Isoherranen, N., Unadkat, J. D., Hebert, M. F. and Mao, Q.: Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm. Drug Dispos., 31: 228-242 (2010).
17. Eckhardt, M., Langkopf, E., Mark, M., Tadayyon, M., Thomas, L., Nar, H., Pfrengle, W., Guth, B., Lotz, R., Sieger, P., Fuchs, H. and Himmelsbach, F.: 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 50: 6450-6453 (2007).
18. Graefe-Mody, E. U., Padula, S., Ring, A., Withopf, B. and Dugi, K. A.: Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr. Med. Res. Opin., 25: 1963-1972 (2009).
19. Kendall, D. M., Cuddihy, R. M. and Bergenstal, R. M.: Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Eur. J. Intern. Med., 20: S329-S339 (2009).
20. Forst, T., Uhlig-Laske, B., Ring, A., Graefe-Mody, U., Friedrich, C., Herbach, K., Woerle, H.-J. and Dugi, K. A.: Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet. Med., 27: 1409-1419 (2010).
21. Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A. and Elliott, P.: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 339: b4731 (2009).
22. Karim, A., Laurent, A., Munsaka, M., Wann, E., Fleck, P. and Mekki, Q.: Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J. Clin. Pharmacol., 49: 1210-1219 (2009).
23. Kirchheiner, J., Brockmoller, J., Meineke, I., Bauer, S., Rohde, W., Meisel, C. and Roots, I.: Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther., 71: 286-296 (2002).
24. FDA Draft Guidance on Drug Interactions. US FDA Center for Biologics Evaluation and Research (CBER), Sept 2006. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072119.pdf (accessed 13 Oct 2010).
25. Rettie, A. E. and Jones, J. P.: Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol., 45: 477-494 (2005).
26. Deacon, C. F. and Holst, J. J.: Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs, 19: 133-140 (2010).
27. Lewin, A. J., Arvay, L., Liu, D., Patel, S. and Woerle, H.-J.: Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Presented at the European Association for the Study of Diabetes 46th Annual Meeting, Stockholm, Sweden. 20-24 September 2010, poster no. 821.